Further studies have shown that soluble EphA2-Fc and EphA3-Fc receptor constructs inhibit tumour angiogenesis and growth in vivo (Brantley et al, 2002), providing the first functional evidence for EphA receptor regulation of tumour angiogenesis. The gene discussed is EPHA2; the disease is neoplasm.